Cautiously optimistic on Transenterix, BTIG’s Sean Lavin believes the sale of SurgiBot assets was a strategic play “forward.”
TransEnterix, Inc. (NYSE:TRXC) has revealed that it has shaken hands with Great Belief International Limited (GBIL) to transfer SurgiBot System ownership to the …
Transenterix Inc (NYSEAMERICAN:TRXC) announced its operating and financial results for the third quarter of 2017. “We are very excited about the progress we …
Both TRXC and MNKD offer potentially big rewards, but at what cost?
Rick Wise: High surgeon intrigue in TRXC’s Senhance; Mark Massaro: EXAS could hit 2.7M in tests by 2021.
A glimpse into two of the market’s most volatile stocks right now.
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
Did this $4 billion fund make the right call on these two soaring biotechs?
Rick Wise: A lot of work left for TRXC- but end of the road holds a massive prospective audience.
Sean Lavin: TRXC investor focus to turn to U.S.